Eesti - eesti - Ravimiamet

zentiva k.s. - palderjanijuur - kaetud tablett - 445mg 60tk; 445mg 15tk; 445mg 30tk

Eesti - eesti - Ravimiamet

queisser pharma gmbh & co. kg - viirpuuvili+melissileht+rosmariinileht+palderjanijuur - suukaudne vedelik - 250ml 1tk; 750ml 1tk; 1000ml 1tk; 500ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international bv - elus nõrgestatud lindude nakkav bronhiidi viiruse variant tüvi 4-91 - immunoloogilised ained - kana - kanade aktiivne immuniseerimine, et vähendada infektsioosse bronhiidi hingamisteede nähud, mida põhjustab varianti tüvi ib 4-91.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - elus lindude nakkav bronhiit viirus, tüvi d388 - live viral vaccines, domestic fowl - kana - kana aktiivseks immuniseerimiseks, et vähendada infektsioosse bronhiidi qx-tüüpi variantide põhjustatud lindude nakkusliku bronhiidi hingamisteede nähud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Eesti - eesti - Ravimiamet

genera d.d. - lindude nakkava bronhiidi viirusvaktsiin - lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks - 5000annus 10tk; 1000annus 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - tsefaloonium - intramammaarsuspensioon - 250mg 3g 3g 60tk; 250mg 3g 3g 24tk